Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 16/20 | 0.77 |
| ▸ | PRKCA | P17252 | 3/20 | 0.64 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.59 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.59 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.59 |
| ▸ | EGFR | P00533 | 2/20 | 0.56 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.55 |
| ▸ | CDK2 | P24941 | 4/20 | 0.55 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.55 |
| ▸ | CLK1 | P49759 | 3/20 | 0.53 |
| ▸ | CLK2 | P49760 | 3/20 | 0.53 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.53 |
| ▸ | CDK4 | P11802 | 1/20 | 0.53 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.53 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.53 |
| ▸ | CCND1 | P24385 | 1/20 | 0.53 |
| ▸ | CCND3 | P30281 | 1/20 | 0.53 |
| ▸ | MTOR | P42345 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6576849 | 1.00 | CDK1 (0.77) | CDK1PRKCACCNB1CCNB2CCNB3 | |
| SCHEMBL6576348 | 0.92 | CDK1 (0.75) | CDK1PRKCACCNB1CCNB2CCNB3 | |
| SCHEMBL6578423 | 0.92 | CDK1 (0.75) | CDK1PRKCACCNB1CCNB2CCNB3 | |
| SCHEMBL6576853 | 0.92 | CDK1 (0.77) | CDK1PRKCACCNB1CCNB2CCNB3 | |
| SCHEMBL6576857 | 0.92 | CDK1 (0.77) | CDK1PRKCACCNB1CCNB2CCNB3 | |
| SCHEMBL6577004 | 0.89 | CDK1 (0.68) | CDK1PRKCACCNB1CCNB2CCNB3 | |
| SCHEMBL6577007 | 0.89 | CDK1 (0.68) | CDK1PRKCACCNB1CCNB2CCNB3 | |
| SCHEMBL6574948 | 0.88 | CDK1 (0.83) | CDK1PRKCACCNB1CCNB2CCNB3 | |
| SCHEMBL6574952 | 0.88 | CDK1 (0.83) | CDK1PRKCACCNB1CCNB2CCNB3 | |
| SCHEMBL5840382 | 0.87 | CDK1 (1.00) | CDK1PRKCACCNB1CCNB2CCNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6767906-B2 | INHIBIT P34CDC2/CYCLIN BCDC13 KINASE AND PROTEIN TYROSINE KINASE PP60C-SRC AND CAN BE USED FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES, FOR EXAMPLE CHEMOTHERAPY OF TUMOURS OR OSTEOPOROSIS. | NOVARTIS AG (CH) | 2004-07-27 | — | — | US | disclosed |
| EP-1153024-B1 | 2-AMINO-6-ANILINO-PURINES AND THEIR USE AS MEDICAMENTS | NOVARTIS AG (CH) | 2004-04-28 | — | — | EP | disclosed |
| US-20020016329-A1 | 2-Amino-6-anilino-purines and their use as medicaments | NOVARTIS AG (CH) | 2002-02-07 | — | — | US | disclosed |
| EP-1153024-A1 | 2-AMINO-6-ANILINO-PURINES AND THEIR USE AS MEDICAMENTS | Novartis AG (CH) | 2001-11-14 | — | — | EP | disclosed |
| WO-2000049018-A1 | 2-AMINO-6-ANILINO-PURINES AND THEIR USE AS MEDICAMENTS | NOVARTIS AG (CH) | 2000-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016329-A1 | 2-Amino-6-anilino-purines and their use as medicaments | CDK14, CDK1, CCNB1 | CDK1 2/4885PRKCA 365/4885CCNB1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.